Natural history of HIV-1 infection

Clinics in Dermatology

Volumn 18, Issue 4, 2000, Pages 389-399

  Touloumi, Giota ^a   Hatzakis, Angelos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MARKER;

ADULT; CHILD; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW;

DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMAN;

EID: 0033833742     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(99)00134-0     Document Type: Review

References (152)

1. Feinberg M.B. Changing the natural history of HIV disease. Lancet. 348:1996;239-246.
2. Piatak M., Saag M., Yang L., et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 259:1993;1749-1754.
3. Daas E.S., Moudgil T., Meyer R.D., et al. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med. 324:1991;961-964.
4. Tindall B., Cooper D.A. Primary HIV infection Host responses and intervention strategies . AIDS. 5:1991;1-14.
5. Busch M.P., El-Amad Z., Sheppard H.W., Ascher M.S., et al. Primary HIV-1 infection. N Engl J Med. 325:1991;733.
6. Clark S.J., Saag M.S., Decker W.D., et al. High titers of cytopathic virus in plasma of patients with symptomatic primary infection. N Engl J Med. 324:1991;954-960.
7. Koup R.A., Safrit J.T., Cao Y., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 68:1994;4650-4655.
8. Borrow P., Lewicki H., Hahn B.H., et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 68:1994;6103-6110.
9. Mackewicz C.E., Yang L.C., Lifson J.D., et al. Non-cytolytic CD8 T-cell anti-HIV responses in primary infection. Lancet. 344:1994;1671-1673.
10. Henrard D.R., Phillips J.F., Muenz L.R., et al. Natural history of HIV-1 cell free viremia. JAMA. 274:1995;554-558.
11. Jurriaans S., Van Gemen B., Weverling G.L., et al. The natural history of HIV-1 infection Virus load and virus phenotype independent determinants of clinical course? Virology. 204:1994;223-233.
12. Gupta P., Kingsley L., Armstrong J., et al. Enhanced expression of human immunodeficiency virus type 1 correlates with development of AIDS. Virology. 196:1993;586-595.
13. O'Brien T.R., Hoover D.R., Rosenberg P.S., et al. Evaluation of secular trends in CD4+ lymphocyte loss among human immunodeficiency virus type 1 (HIV-1)-infected men with known dates of seroconversion. Am J Epidemiol. 142:1995;636-642.
14. O'Brien T.R., Blattner W.A., Waters D., et al. Serum HIV-RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 276:1996;105-110.
15. Mellors J.W., Kingsley L.A., Rinaldo C.R., et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 122:1995;573-579.
16. Mellors J.W., Rinaldo C.H., Gupta P., et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1996;1167-1170.
17. Coffin J.M. HIV population dynamics in vivo Implications for genetic variation, pathogenesis and therapy . Science. 267:1995;483-489.
18. Ho D.D., Moudgil T., Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med. 321:1989;1621-1625.
19. Ho D.D., Neumann A.U., Perelson A.S., et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:1995;123-126.
20. Perelson A.J., Neumann A.U., Markowitz M., et al. HIV-1 dynamics in vivo Virion clearance rate, infected cell life-span, and viral generation time . Science. 271:1996;1582-1586.
21. Wei X., Ghosh S.K., Taylor M.E., et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:1995;117-122.
22. Phillips A.N., Lee C.A., Elford J., et al. Serial CD4 lymphocyte counts and development of AIDS. Lancet. 337:1991;389-392.
23. Lang W., Perkins H., Anderson R.E., et al. Patterns of T lymphocyte changes with human immunodeficiency virus infection From seroconversion to the development of AIDS . J Acquir Immune Defic Syndr. 2:1989;63-69.
24. Cozzi-Lepri A.C., Sabin C.A., Tezzotti P., et al. Is there a general tendency for rate of CD4+ lymphocyte count decline to speed up during HIV infection? Evidence from the Italian Seroconversion Study. J Infect Dis. 175:1997;775-780.
25. Touloumi G., Hatzakis A., Rosenberg P.S., et al. Effects of age at seroconversion and baseline HIV-RNA level on the loss of CD4+ cells among persons with hemophilia. AIDS. 12:1998;1691-1697.
26. Margolick J.B., Munoz A., Donnenberg A.D., et al. Failure of T-cell homeostatis preceding AIDS in HIV-1 infection. Nat Med. 7:1995;674-680.
27. Eyster M.E., Gail M.H., Ballard J.O., et al. Natural history of human immunodeficiency virus infection in hemophiliacs Effects of T-cell subsets, platelet counts and age . Ann Intern Med. 107:1987;1-6.
28. Levy J.A. The mysteries of HIV Challenges for therapy and prevention . Nature. 333:1988;519-522.
29. McDonald R.A., Mayers D.L., Chung R.C.Y., et al. Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T-cell function. J Virol. 71:1997;1871-1879.
30. Levy J.A. HIV and the pathogenesis of AIDS. 2nd ed. 1998;ASM Press, Washington, DC.
31. Crowe S., Carlin J.B., Steward K.I., et al. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignacies in HIV-infected persons. J Acquir Immune Defic Syndr. 4:1991;770-776.
32. 6/l. AIDS. 9:1995;145-152.
33. Katz M.A., Hessol N.A., Buchbinder S.P., et al. Temporal trends of opportunistic infections and malignacies in homosexual men with AIDS. J Infect Dis. 170:1994;198-202.
34. Mocroft A., Johnson M.A., Sabin C.A., et al. Staging system for clinical AIDS patients. Lancet. 346:1995;12-17.
35. Brodt R.H., Kamps B.S., Gute P., et al. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS. 11:1998;1731-1738.
36. Strathdee S.A., O'Shaughnessy M.V., Montaner J.S.G., et al. A decade of research on the natural history of HIV infection Part 1. Marker . Clin Invest Med. 16:1996;111-120.
37. Strathdee S.A., O'Shaughnessy M.V., Montaner J.S.G., et al. A decade of research on the natural history of HIV infection Part 2. Cofactors . Clin Invest Med. 16:1996;121-130.
38. Brookmayer R., Gail M.H., Polk B.R. The prevalent cohort study and the acquired immunodeficiency virus. Am J Epidemiol. 126:1987;14-24.
39. Features of children perinatally infected with HIV-1 surviving longer than 5 years. Lancet. 343:1994;191-195.
40. Carre N., Deveau C., Belanger F., et al. Effect of age and exposure group on the onset of AIDS in heterosexual and homosexual HIV-1 infected patients. AIDS. 8:1994;797-802.
41. Moss A.R., Bacchetti P., Osmond D., et al. Seropositivity for HIV and the development of AIDS or ARC Three-year follow-up of the San Francisco General Hospital Cohort . BMJ. 296:1998;745-750.
42. Veugelers P.J., Strathdee S.A., Tindall B., et al. Increasing age is associated with faster progression to neoplasms but not opportunistic infections in HIV-1 infected homosexual men. AIDS. 8:1994;1471-1475.
43. Blaxhult A., Granath F., Lindmon K., et al. The influence of age on the latency period to AIDS in people infected by HIV through blood transfusion. AIDS. 4:1990;125-129.
44. Kopec-Schrader E., Tindall B., Learmont J., et al. Development of AIDS in people with transfusion-acquired HIV infection. AIDS. 7:1993;1009-1013.
45. Mariotto A.B., Mariotti S., Pezzotti P., et al. Estimation of the acquired immunodeficiency syndrome incubation period in intravenous drug users A comparison with male homosexuals . Am J Epidemiol. 135:1992;428-437.
46. Goedert J.J., Kessler C.M., Aledort L.M., et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with haemophilia. N Engl J Med. 321:1989;1141-1148.
47. Lee C.A., Phillips A.N., Elford J., et al. Progression of HIV disease in a haemophilic cohort followed for 11 years and the effect of treatment. BMJ. 303:1991;1093-1096.
48. Darby S.C., Ewart D.W., Giangrande P.L.F., et al. Mortality before and after HIV infection in the complete UK population of haemophiliacs. Nature. 377:1995;79-82.
49. Darby S.C., Ewart D.W., Giangrande P.L.F., et al. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet. 347:1996;1573-1579.
50. Touloumi G., Karafoulidou A., Gialeraki A., et al. Determinants of progression of HIV infection in a Greek hemophilia cohort followed for up to 16 years after seroconversion. J Acquir Immune Defic Syndr. 19:1998;89-97.
51. Coates R.A., Farewell V.T., Raboud J., et al. Cofactors of progression to acquired immunodeficiency syndrome in a cohort of male sexual contacts of men with human immunodeficiency virus disease. Am J Epidemiol. 132:1990;717-722.
52. Hessol N.A., Kolbin B.A., Van Griensven G.J.P., et al. Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohort in Amsterdam, New York City, and San Francisco, 1978-1991. Am J Epidemiol. 139:1994;1077-1087.
53. Polk B.F., Fox R., Brookmeyer R., et al. Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. N Engl J Med. 316:1987;61-66.
54. + T-cell counts . J Acquir Immune Defic Syndr. 4:1991;970-975.
55. Touloumi G, Hatzakis A, Karafoulidou A, et al. The slope of change in CD4 counts as prognostic factor in the progression of HIV infection. Tenth International Conference on AIDS. Yokohama, Japan, August 7-12, 1994.
56. Disease progression and early predictors of AIDS in HIV-seroconverted injecting drug users. AIDS. 6:1992;421-426.
57. + T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 332:1995;143-149.
58. Hessol NA, Palacio H. Gender, ethnicity and transmission exposure category variation in HIV disease progression.
59. Munoz A., Sabin C.A., Phillips A.N. The incubation period of AIDS. AIDS. 11:(Suppl A):1997;S69-S76.
60. Sabin C.A. Vancouver Conference Review Natural history . AIDS Care. 9:1997;98-103.
61. Cohen M. Natural history of HIV infection in women. Obstet Gynecol Clin North Am. 4:1997;743-759.
62. Anastos K., Denenberg R., Solomon L. Human immunodeficiency virus infection in women. Med Clin North Am. 81:1997;533-553.
63. Suligoi B. The natural history of human immunodeficiency virus infection among women as compared with men. Sex Transm Dis. 24:1997;77-83.
64. Morgan D., Maude G.H., Malamba S.S., et al. HIV-1 disease progression and AIDS-defining disorders in rural Uganda. Lancet. 350:1997;245-250.
65. Jougla E., Peguignot F., Carbon C., et al. AIDS-related conditions Study of a representative sample of 1203 patients deceased in 1992 in France . Int J Epidemiol. 25:1996;190-197.
66. Weisser M., Rudin C., Battegay M., et al. Does pregnancy influence the course of HIV infection? J Acquir Immune Defic Syndr. 17:1998;404-410.
67. Farzadegan H., Hoover D.R., Astemborski J., et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet. 352:1998;1510-1514.
68. Hoover DR, Saah AJ, Guccione M, et al. Observed HIV-1 disease progression times in gay men with access to treatment. Eleventh International Conference on AIDS. Vancouver, July 1996 (abstract TuC 435).
69. Sinicco A, Fora R, Sciandra M, et al. Faster progression to AIDS in recent seroconverters to HIV. Eleventh International Conference on AIDS. Vancouver, July 1996 (abstract WeB 3254).
70. Galai N, Cozzi Lepri A, Vlahov D, for the Human Immunodeficiency Virus Italian Seroconversion Study. Temporal trends of initial CD4 cell counts following human immunodeficiency virus seroconversion in Italy, 1985-1992. Am J Epidemiol 1996;143:278-82.
71. Coates T.J., Stall R.D., Catania J.A., et al. Behavioural factors in the spread of HIV infections. AIDS. 2:(Suppl 1):1988;S239-S246.
72. Hogg R.S., Strathdee S.A., Craib K.J.P., et al. Lower socioeconomic status and shorter survival following HIV infection. Lancet. 344:1994;1120-1124.
73. Simon P.A., Hu D.J., Diaz T., et al. Income and AIDS rates in Los Angeles Country. AIDS. 9:1995;281-284.
74. Semba R.D., Miotti P.G., Chiphangwi J.D., et al. Maternal vitamin A deficiency and mother-to-child transmission of HIV-1. Lancet. 343:1994;1593-1597.
75. Semba R.D., Graham N.M.H., Caiaffa W.T., et al. Increased mortality associated with vitamin A deficiency during human immunodeficiency virus type 1 infection. Arch Intern Med. 153:1993;2149-2154.
76. Bwago J.J., Nagelkerke N.J.D., Moses S., et al. Comparison of the decline in CD4 counts in HIV-1 seropositive female sex workers and women from the general population in Nairobi, Kenya. J Acquir Immune Defic Syndr Hum Retrovirol. 10:1995;457-461.
77. Lo S.C., Hayes M.M., Wang R.Y., et al. New discovered mycoplasma isolated from patients with HIV. Lancet. 338:1991;1415-1418.
78. Capobianchi M.R., Barresi C., Borghi P., et al. Human immunodeficiency virus type 1 gp120 stimulates cytomegalovirus replication in monocytes Possible role of endogenous interleukin-8 . J Virol. 71:1997;1591-1597.
79. Ho W.Z., Ayyavoo V., Srinivasan A., et al. Human immunodeficiency virus type 1 tat gene enhances human cytomegalovirus gene expression and viral replication. AIDS Res Hum Retroviruses. 7:1991;689-695.
80. Levy J.A., Landay A., Lennette E.T. HHV-6 inhibits HIV-1 replication in cell culture. J Clin Microbiol. 28:1990;2362-2364.
81. Sabin C.A., Phillips A.N., Lee C.A., et al. The effect of CMV infection on progression of human immunodeficiency virus disease in a cohort of haemophilic men followed for up to 13 years from seroconversion. Epidemiol Infect. 114:1995;361-372.
82. Becherer P.R., Smiley M.L., Mathews T.J., et al. Human immunodeficiency virus-1 disease progression in hemophiliacs. Am J Hematol. 34:1990;204-209.
83. Rabkin C.S., Hatzakis A., Griffiths P.D., et al. Cytomegalovirus infection and risk of AIDS in human immunodeficiency virus-infected hemophilia patients. J Infect Dis. 168:1993;1260-1263.
84. Telfer P., Sabin C., Devereux H., et al. The progression of HIV-associated liver disease in a cohort of haemophilic patients. Br J Haematol. 87:1994;555-561.
85. Zylberbery H., Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis. 23:1996;1117-1125.
86. Vento S., Garofano T., Renzini C., et al. Enhancement of hepatitis C virus replication and liver damage in HIV coinfected patients on antiretroviral combination therapy. AIDS. 12:1988;116-117.
87. Gallo P., Frei K., Rordorf C., et al. Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system An evaluation of cytokines in cerebrospinal fluid . J Neuroimmunol. 23:1989;109-116.
88. Steel C.M., Ludlam C.A., Beatson D., et al. HLA halpotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet. 1:1988;1185-1188.
89. Kaslow R.A., Duquesnoy R., Van Raden M., et al. A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. Lancet. 335:1990;927-930.
90. Itescu S., Mathus-Wagh U., Skovron M.L., et al. HLA-B35 is associated with accelerated progression to AIDS. J Acquir Immune Defic Syndr. 5:1991;37-45.
91. Kaslow R.A., Carrington M., Apple R., et al. Influence of combinations of human major histocompatibility complex genes on the cource of HIV-1 infection. Nat Med. 2:1996;405-411.
92. Klein M.R., Keet I.P.M., D'Amaro J., et al. Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam cohort of homosexual men. J Infect Dis. 169:1994;1244-1249.
93. Mann D.L., Murray C., Yarchoan R., et al. HLA antigen frequencies in HIV-1 seropositive disease-free individual and patients with AIDS. J Acquir Immune Defic Syndr. 1:1988;13-17.
94. Deng H., Liu R., Ellmeier W., et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature. 381:1996;661-666.
95. Dragic T., Litwin V., Allaway G.P., et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 381:1996;667-673.
96. Choe H., Farzan M., Sun Y., et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 85:1996;1135-1148.
97. Feng Y., Broder C.C., Kennedy P.E., et al. HIV-1 entry cofactor functional cDNA cloning of a seven-transmembrane domain, G-protein coupled receptor. Science. 272:1996;872-877.
98. O'Brien S.J. AIDS A role for host genes . Hosp Pract. 33:1998;53-69.
99. Samson M., Libert F., Doranz B.J., et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles for the CCR-5 chemokine receptor genes. Nature. 382:1996;722-725.
100. Dean M., Carrington M., Winkler C., et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CCR5 structural gene. Science. 273:1996;1856-1862.
101. Huang H., Paxton W.A., Wolinsky S.M., et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 2:1996;1240-1243.
102. Eugen-Olsen J., Iversen A.K.N., Garred P., et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS. 11:1997;305-310.
103. Meyer L., Magierowska M., Hubert J.-B., et al. Early protective effect of CCR-5Δ32 heterozygosity on HIV-1 disease progression Relationship with viral load . AIDS. 11:1997;F73-F78.
104. Lee B., Doranz B.J., Rana S., et al. Influence of CCR2-V64I polymorphism on human immunodeficiency virus type 1 corecepror activity and on chemokine receptor function of CCR2b, CCR3, CCR5 and CXCR4. J Virol. 72:1988;7450-7458.
105. Kostrikis L.G., Huang Y., Moore J.P., et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med. 4:1988;350-353.
106. Winkler C., Modi W., Smith M.W., et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort. Science. 279:1998;389-393.
107. Martin M.P., Dean M., Smith M.W., et al. Genetic acceleration of AIDS progression by a promoter of variant of CCR5. Science. 282:1988;1907-1911.
108. Chang-Mayer C., Seto D., Tateno M., et al. Biologic features of HIV that correlate with virulence in the host. Science. 240:1988;80-82.
109. Tersmette M., Gruters R.A., de Wolf F., et al. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome Studies on sequential HIV isolates . J Virol. 63:1989;2118-2125.
110. Cornelissen M., Mulder-Kampina G., Veenstra J., et al. Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population. J Virol. 69:1995;1810-1818.
111. Saag M.S., Hammer S.M., Lange J.M.A. Pathogenicity and diversity of HIV and implications for clinical management A review . J Acquir Immune Defic Syndr. 7:(Suppl 2):1994;S2-S10.
112. Koot M., Vos A.H.V., Keef R.P.M., et al. HIV-1 biological phenotype in long-term infected individuals, evaluated with an MT-2 concultivation assay. AIDS. 6:1992;49-54.
113. Goudsmit J. The role of viral diversity in HIV pathogenesis. J Acquir Immune Defic Syndr Hum Retrovirol. 10:(Suppl 1):1995;S15-S19.
114. Deacon N.J., Tsykin A., Solomon A., et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science. 270:1995;988-991.
115. Kirchhoff F., Greenough T.C., Brettler D.B., et al. Brief report Absence of intact nef sequences in a long-term survivor with non-progressive HIV-1 infection . N Engl J Med. 332:1995;228-232.
116. Huang Y., Zhang Z., Ho D.D. Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection. J Virol. 69:1995;93-100.
117. Graham N.M.H. The role of immunologic and viral marker in predicting clinical outcome in HIV infection. AIDS. 10:(Suppl 5):1996;S21-S25.
118. Fahey J.L., Taylor J.M.G., Detels R., et al. The prognostic value of cellular and serologic markers in infection with HIV-1. N Engl J Med. 322:1990;166-172.
119. Phillips A.N. Studies of prognostic markers in HIV infection Implications for pathogenesis . AIDS. 6:1991;1391-1394.
120. Taylor J.M.G., Fahey J.L., Detels R., et al. CD4 percentage, CD4 number and CD4:CD8 ratio in HIV infection Which to choose and how to use . J Acquir Immune Defic Syndr. 2:1989;114-124.
121. Stein D.S., Korvick J.A., Vermund S.H. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease A review . J Infect Dis. 165:1992;352-363.
122. Connors M., Kovacs J.A., Krevat S., et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med. 5:1997;533-540.
123. Clerici M., Sheares G.M. The Th1-Th2 hypothesis of HIV infection New insights . Immunol Today. 15:1993;575-581.
124. Klein S.A., Dobmeyer J.M., Dobmeyer T.S., et al. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS. 11:1997;1111-1118.
125. Hyjek E., Lischner H.W., Hyslop T., et al. Cytokine patterns during progression to AIDS in children with perinatal HIV infection. J Immunol. 155:1995;4060-4071.
126. Jason J., Sleeper Z.A., Donfield S.M., et al. Evidence for a shift from type I lymphocyte pattern with HIV disease progression. J Acquir Immune Defic Syndr Hum Retrovirol. 10:1995;471-476.
127. Mackewicz C.E., Ortega H.W., Levy J.A. CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest. 87:1991;1462-1466.
128. Sheppard H.W., Lang W., Ascher M.S., et al. The characterization of non-progressors Long-term HIV-1 infection with stable CD4+ T-cell levels . AIDS. 7:1993;1159-1166.
129. Buchbinder S.P., Katz M.H., Hessol N.A., et al. Long-term HIV-1 infection without immunologic progression. AIDS. 8:1994;1123-1128.
130. Schrager L.K., Young J.M., Fowler M.G., et al. Long-term survivors of HIV-1 infection Definitions and research challenges . AIDS. 8:1994;S95-S108.
131. Barker E., Mackewicz C.E., Levy J.A. Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus Implications for long-term survival . Proc Natl Acad Sci U S A. 92:1995;1135-1139.
132. Fuchs D., Hansen A., Reibnegger G., et al. Neopterin as a marker for cell-mediated immunity Application in HIV infection . Immunol Today. 9:1988;150-155.
133. Osmond D.H., Shiboski S., Bacchetti P., et al. Immune activation markers and AIDS prognosis. AIDS. 5:1991;505-511.
134. 2-microglobulin, and neopterin serum levels in patients with Kaposi's sarcoma and AIDS. J Acquir Immune Defic Syndr. 4:1991;871-880.
135. Part I Immunologic markers of AIDS progression: Consistently across five HIV-infected cohorts . AIDS. 8:1994;911-921.
136. Paul D.A., Falk L.A., Kessler H.A. Correlation of serum HIV antigen and antibody with clinical status in HIV-infected patients. J Med Virol. 22:1987;357-363.
137. Mellors J.W., Munoz A., Giorgi J.V., et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 126:1997;946-954.
138. Roos M.T.L., de Leeuw N.A.S.M., Claessen F.A.P., et al. Viro-immunological studies in acute HIV-1 infection. AIDS. 8:1994;1533-1538.
139. Henrard D.R., Daar E., Farzadegan H., et al. Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol. 9:1995;305-310.
140. de Wolf F., Spijkerman I., Schellekeus P.T.L., et al. AIDS prognosis based on HIV-RNA, CD4+ T-cell count and function Markers with reciprocal predictive value over time after seroconversion . AIDS. 1:1997;1799-1806.
141. Coombs R.W., Welles S.L., Hooper C., et al. Association of plasma immunodeficiency virus type-1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis. 174:1996;704-712.
142. Wells S.L., Jackson J.B., Yen-Lieberman B., et al. Prognostic value of plasma HIV-RNA levels in patients with advanced disease with little or no zidovudine therapy. J Infect Dis. 174:1996;696-703.
143. Haynes B.F., Pantaleo G., Fauci A. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 271:1996;324-328.
144. Phillips A.N., Sabin C.A., Bofill M., et al. Are there two types of response to HIV? (letter) Lancet. 341:1993;1023-1024.
145. Domachowske J.B. Pediatric human immunodeficiency virus infection. Clin Microbiol Rev. 9:1996;448-468.
146. Barnhart H.X., Caldwell M.B., Thomas P., et al. Natural history of human immunodeficiency virus disease in perinatally infected children: An analysis from the Pediatric Spectrum of Disease Project. Pediatrics. 97:1996;710-716.
147. Krasinski K., Borkowsky W., Holzman R.S. Prognosis of human immunodeficiency virus infection in children and aadolescents. Pediatr Infect Dis. 8:1989;216-220.
148. Carey V.J., Yong F.H., Frenkel L.M., et al. Pediatric AIDS prognosis using somatic growth velocity. AIDS. 12:1998;1361-1369.
149. Auger I., Thomas P., DeGruttola V., et al. Incubation periods for paediatric AIDS patients. Nature. 336:1988;575-577.
150. Scott G.B., Hutto C., Makuch R.W., et al. Survival in children with perinatally acquired human immunodeficiency type 1 infection. N Engl J Med. 321:1989;1791-1796.
151. Koracs A., Frederick T., Church J., et al. CD4 T-lymphocyte counts and Pneumocystis carinni pneumonia in pediatric HIV infection. JAMA. 265:1991;1698-1703.
152. Marum LH, Begenda D, Guay L, et al. Three-year mortality in a cohort of HIV-1 infected and uninfected Ugandan children. Eleventh International Conference on AIDS. Vancouver, July 1996 (abstract WeB 312).